All News Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Delayed Nasdaq Other stock markets 07:39:56 21/05/2024 pm IST			5-day change	1st Jan Change
1.722 ^USD	-1.05%		-4.87%	-1.05%

11/03	Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	MT
11/03	Top Premarket Gainers	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sonnet BioTherapeutics : Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Form 8-K	20/05	PU
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference	03/05	NE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy at the AACR 2024 Annual Meeting	20/03	AQ
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	11/03	MT
Top Premarket Gainers	11/03	MT
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080	11/03	CI
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers	01/03	AQ
Chardan Cuts PT on Sonnet BioTherapeutics to $30 From $75 to Reflect Higher Projected Future Share Count, Keeps Buy Rating	15/02	MT
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update	15/02	AQ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	14/02	CI
North American Morning Briefing : Stock Futures -2-	09/02	DJ
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy	22/12	AQ
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	20/12	DJ
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update	15/12	AQ
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	15/12	CI
North American Morning Briefing : Traders Await -2-	13/12	DJ
Ladenburg Thalmann Starts Sonnet BioTherapeutics Holdings With Buy Rating, $7 Price Target	27/11	MT
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering	26/23/26	AQ
Sector Update: Health Care Stocks Retreating Late Afternoon	26/23/26	MT
Top Midday Decliners	25/23/25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

All News

Filters